In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

(March 30, 2026) by Angus Liu

Disclosed in January 2026, Roche paid $100 million for a nonexclusive license to patents from Structure Therapeutics. This strategic move protects Roche’s oral GLP-1 candidate, CT-996, from potential patent litigation.